Global RNAi for Therapeutic Market by Manufacturers, Regions, Type and Application, Forecast to 2021

According to Custom Market Inights analysis, The global rnai for therapeutic market is expected to register a healthy CAGR during the period from 2016 to 2025. This report studies the rnai for therapeutic status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the rnai for therapeutic by product type and applications/end industries.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Scope of the Report:

This report focuses on the RNAi for Therapeutic in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

Market Segment by Type, covers

siRNA

miRNA

shRNA

Market Segment by Applications, can be divided into

Cancer

Cardiovascular

HBV

Other

There are 13 Chapters to deeply display the global RNAi for Therapeutic market.

Chapter 1, to describe RNAi for Therapeutic Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of RNAi for Therapeutic, with sales, revenue, and price of RNAi for Therapeutic, in 2015 and 2016;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;

Chapter 4, to show the global market by regions, with sales, revenue and market share of RNAi for Therapeutic, for each region, from 2011 to 2016;

Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;

Chapter 11, RNAi for Therapeutic market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;

Chapter 12 and 13, to describe RNAi for Therapeutic sales channel, distributors, traders, dealers, appendix and data source.

Table of Contents

Global RNAi for Therapeutic Market by Manufacturers, Regions, Type and Application, Forecast to 2021

1 Market Overview

1.1 RNAi for Therapeutic Introduction

1.2 Market Analysis by Type

1.2.1 siRNA

1.2.2 miRNA

1.2.3 shRNA

1.3 Market Analysis by Applications

1.3.1 Cancer

1.3.2 Cardiovascular

1.3.3 HBV

1.4 Market Analysis by Regions

1.4.1 North America (USA, Canada and Mexico)

1.4.1.1 USA

1.4.1.2 Canada

1.4.1.3 Mexico

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany

1.4.2.2 France

1.4.2.3 UK

1.4.2.4 Russia

1.4.2.5 Italy

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China

1.4.3.2 Japan

1.4.3.3 Korea

1.4.3.4 India

1.4.3.5 Southeast Asia

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil

1.4.4.2 Egypt

1.4.4.3 Saudi Arabia

1.4.4.4 South Africa

1.4.4.5 Nigeria

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Alnylam Pharmaceuticals

2.1.1 Business Overview

2.1.2 RNAi for Therapeutic Type and Applications

2.1.2.1 Type 1

2.1.2.2 Type 2

2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.2 Arbutus Biopharma (Tekmira)

2.2.1 Business Overview

2.2.2 RNAi for Therapeutic Type and Applications

2.2.2.1 Type 1

2.2.2.2 Type 2

2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.3 Arrowhead

2.3.1 Business Overview

2.3.2 RNAi for Therapeutic Type and Applications

2.3.2.1 Type 1

2.3.2.2 Type 2

2.3.3 Arrowhead RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.4 Dicerna Pharmaceuticals

2.4.1 Business Overview

2.4.2 RNAi for Therapeutic Type and Applications

2.4.2.1 Type 1

2.4.2.2 Type 2

2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.5 Mirna Therapeutics

2.5.1 Business Overview

2.5.2 RNAi for Therapeutic Type and Applications

2.5.2.1 Type 1

2.5.2.2 Type 2

2.5.3 Mirna Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.6 Quark Pharmaceuticals

2.6.1 Business Overview

2.6.2 RNAi for Therapeutic Type and Applications

2.6.2.1 Type 1

2.6.2.2 Type 2

2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.7 RXi Pharmaceuticals

2.7.1 Business Overview

2.7.2 RNAi for Therapeutic Type and Applications

2.7.2.1 Type 1

2.7.2.2 Type 2

2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.8 Silence Therapeutics

2.8.1 Business Overview

2.8.2 RNAi for Therapeutic Type and Applications

2.8.2.1 Type 1

2.8.2.2 Type 2

2.8.3 Silence Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.9 Benitec Biopharma

2.9.1 Business Overview

2.9.2 RNAi for Therapeutic Type and Applications

2.9.2.1 Type 1

2.9.2.2 Type 2

2.9.3 Benitec Biopharma RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.10 miRagen Therapeutics

2.10.1 Business Overview

2.10.2 RNAi for Therapeutic Type and Applications

2.10.2.1 Type 1

2.10.2.2 Type 2

2.10.3 miRagen Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.11 Sylentis

2.11.1 Business Overview

2.11.2 RNAi for Therapeutic Type and Applications

2.11.2.1 Type 1

2.11.2.2 Type 2

2.11.3 Sylentis RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.12 Gradalis

2.12.1 Business Overview

2.12.2 RNAi for Therapeutic Type and Applications

2.12.2.1 Type 1

2.12.2.2 Type 2

2.12.3 Gradalis RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.13 Sirnaomics

2.13.1 Business Overview

2.13.2 RNAi for Therapeutic Type and Applications

2.13.2.1 Type 1

2.13.2.2 Type 2

2.13.3 Sirnaomics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.14 Silenseed

2.14.1 Business Overview

2.14.2 RNAi for Therapeutic Type and Applications

2.14.2.1 Type 1

2.14.2.2 Type 2

2.14.3 Silenseed RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

3 Global RNAi for Therapeutic Market Competition, by Manufacturer

3.1 Global RNAi for Therapeutic Sales and Market Share by Manufacturer

3.2 Global RNAi for Therapeutic Revenue and Market Share by Manufacturer

3.3 Market Concentration Rate

3.3.1 Top 3 RNAi for Therapeutic Manufacturer Market Share

3.3.2 Top 6 RNAi for Therapeutic Manufacturer Market Share

3.4 Market Competition Trend

4 Global RNAi for Therapeutic Market Analysis by Regions

4.1 Global RNAi for Therapeutic Sales, Revenue and Market Share by Regions

4.1.1 Global RNAi for Therapeutic Sales by Regions (2011-2016)

4.1.2 Global RNAi for Therapeutic Revenue by Regions (2011-2016)

4.2 North America RNAi for Therapeutic Sales and Growth (2011-2016)

4.3 Europe RNAi for Therapeutic Sales and Growth (2011-2016)

4.4 Asia-Pacific RNAi for Therapeutic Sales and Growth (2011-2016)

4.5 South America RNAi for Therapeutic Sales and Growth (2011-2016)

4.6 Middle East and Africa RNAi for Therapeutic Sales and Growth (2011-2016)

5 North America RNAi for Therapeutic by Countries

5.1 North America RNAi for Therapeutic Sales, Revenue and Market Share by Countries

5.1.1 North America RNAi for Therapeutic Sales by Countries (2011-2016)

5.1.2 North America RNAi for Therapeutic Revenue by Countries (2011-2016)

5.2 USA RNAi for Therapeutic Sales and Growth (2011-2016)

5.3 Canada RNAi for Therapeutic Sales and Growth (2011-2016)

5.4 Mexico RNAi for Therapeutic Sales and Growth (2011-2016)

6 Europe RNAi for Therapeutic by Countries

6.1 Europe RNAi for Therapeutic Sales, Revenue and Market Share by Countries

6.1.1 Europe RNAi for Therapeutic Sales by Countries (2011-2016)

6.1.2 Europe RNAi for Therapeutic Revenue by Countries (2011-2016)

6.2 Germany RNAi for Therapeutic Sales and Growth (2011-2016)

6.3 UK RNAi for Therapeutic Sales and Growth (2011-2016)

6.4 France RNAi for Therapeutic Sales and Growth (2011-2016)

6.5 Russia RNAi for Therapeutic Sales and Growth (2011-2016)

6.6 Italy RNAi for Therapeutic Sales and Growth (2011-2016)

7 Asia-Pacific RNAi for Therapeutic by Countries

7.1 Asia-Pacific RNAi for Therapeutic Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific RNAi for Therapeutic Sales by Countries (2011-2016)

7.1.2 Asia-Pacific RNAi for Therapeutic Revenue by Countries (2011-2016)

7.2 China RNAi for Therapeutic Sales and Growth (2011-2016)

7.3 Japan RNAi for Therapeutic Sales and Growth (2011-2016)

7.4 Korea RNAi for Therapeutic Sales and Growth (2011-2016)

7.5 India RNAi for Therapeutic Sales and Growth (2011-2016)

7.6 Southeast Asia RNAi for Therapeutic Sales and Growth (2011-2016)

8 South America, Middle East and Africa RNAi for Therapeutic by Countries

8.1 South America, Middle East and Africa RNAi for Therapeutic Sales, Revenue and Market Share by Countries

8.1.1 South America, Middle East and Africa RNAi for Therapeutic Sales by Countries (2011-2016)

8.1.2 South America, Middle East and Africa RNAi for Therapeutic Revenue by Countries (2011-2016)

8.2 Brazil RNAi for Therapeutic Sales and Growth (2011-2016)

8.3 Saudi Arabia RNAi for Therapeutic Sales and Growth (2011-2016)

8.4 Egypt RNAi for Therapeutic Sales and Growth (2011-2016)

8.5 Nigeria RNAi for Therapeutic Sales and Growth (2011-2016)

8.6 South Africa RNAi for Therapeutic Sales and Growth (2011-2016)

9 RNAi for Therapeutic Market Segment by Type

9.1 Global RNAi for Therapeutic Sales, Revenue and Market Share by Type (2011-2016)

9.1.1 Global RNAi for Therapeutic Sales and Market Share by Type (2011-2016)

9.1.2 Global RNAi for Therapeutic Revenue and Market Share by Type (2011-2016)

9.2 siRNA Sales Growth and Price

9.2.1 Global siRNA Sales Growth (2011-2016)

9.2.2 Global siRNA Price (2011-2016)

9.3 miRNA Sales Growth and Price

9.3.1 Global miRNA Sales Growth (2011-2016)

9.3.2 Global miRNA Price (2011-2016)

9.4 shRNA Sales Growth and Price

9.4.1 Global shRNA Sales Growth (2011-2016)

9.4.2 Global shRNA Price (2011-2016)

10 RNAi for Therapeutic Market Segment by Application

10.1 Global RNAi for Therapeutic Sales Market Share by Application (2011-2016)

10.2 Cancer Sales Growth (2011-2016)

10.3 Cardiovascular Sales Growth (2011-2016)

10.4 HBV Sales Growth (2011-2016)

10.5 Other Sales Growth (2011-2016)

11 RNAi for Therapeutic Market Forecast (2016-2021)

11.1 Global RNAi for Therapeutic Sales, Revenue and Growth Rate (2016-2021)

11.2 RNAi for Therapeutic Market Forecast by Regions (2016-2021)

11.3 RNAi for Therapeutic Market Forecast by Type (2016-2021)

11.4 RNAi for Therapeutic Market Forecast by Application (2016-2021)

12 Sales Channel, Distributors, Traders and Dealers

12.1 Sales Channel

12.1.1 Direct Marketing

12.1.2 Indirect Marketing

12.1.3 Marketing Channel Future Trend

12.2 Distributors, Traders and Dealers

13 Appendix

13.1 Methodology

13.2 Analyst Introduction

13.3 Data Source

Name: (required)

Email: (required)

Phone: (required)

Company: (required)

Designation: (required)

Country: (required)

How can we help you?:

Type the pieces of text below (required)
captcha



Name: (required)

Email: (required)

Phone: (required)

Company: (required)

Designation: (required)

Country: (required)

How can we help you?:

Type the pieces of text below (required)
captcha



Jacob Thomass